Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSC835 in Inherited Metabolic Disorders
NCT02715505Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Oct 2017
- Primary completion
- May 2020
- Modality
- Hematopoietic Stem Cells
01
Overview
Phase 2, open-label, single-arm trial of spanlecortemlocel in Hurler syndrome, metachromatic leukodystrophy (MLD), globoid cell leukodystrophy (GLD) and 1 more, sponsored by Novartis. Primary endpoints: Incidence of infusional toxicities at 48 hours, Incidence of neutrophil recovery at 42 days and 1 more. Planned start Oct 2017; status: withdrawn.
02
Drugs
spanlecortemlocel
03
Conditions
Hurler syndromemetachromatic leukodystrophy (MLD)globoid cell leukodystrophy (GLD)cerebral adrenoleukodystrophy (CALD)
Beyond the preview
Go deeper on NCT02715505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02715505.